ATLANTA, GA USA (UroToday) - This team of researchers evaluated 843 men who had radical prostatectomy for cT3 prostate cancer in the early PSA era (1987 - 1997) and 253 men in the recent ten year period (1998-2008) and evaluated differences in clinicopathologic features, recurrence-free, progression-free, and cancer-specific survival.
PSA screening has significantly altered the demographics of men presenting with cT3 prostate cancer. They found today that a small proportion of men continue to be diagnosed with locally advanced disease. Radical prostatectomy remains the gold standard demonstrating durable cancer control and should be considered for disease management in these men.
Figure 1. Oncologic outcomes for men undergoing RP for cT3 prostate cancer since the advent of routine PSA screening
|
Event |
|
1987 - 1997 (843) |
Recent Group (253) |
|
Biochemical recurrence |
58 |
50 |
0.05 |
|
Systemic progression |
90 |
86 |
0.02 |
|
Prostate cancer death |
95 |
93 |
0.17 |
|
Any cause death |
90 |
98 |
0.32 |
Presented by Christopher Mitchell, Eric Umbreit, Stephen Boorjian, Igor Frank, Matthew Gettman, R. Houston Thompson, Laureano Rangel, and R. Jeffrey Karnes at the American Urological Association (AUA) Annual Meeting - May 19 - 23, 2012 - Georgia World Congress Center - Atlanta, GA USA
